These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 26140381)

  • 21. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
    Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
    PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
    Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
    HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.
    Brunet L; Moodie EEM; Young J; Cox J; Hull M; Cooper C; Walmsley S; Martel-Laferrière V; Rachlis A; Klein MB; ; Cohen J; Conway B; Cooper C; Côté P; Cox J; Gill J; Haider S; Sadr A; Johnston L; Hull M; Montaner J; Moodie E; Pick N; Rachlis A; Rouleau D; Sandre R; Tyndall JM; Vachon ML; Sanche S; Skinner S; Wong D
    Clin Infect Dis; 2016 Jan; 62(2):242-249. PubMed ID: 26400998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.
    Al-Mohri H; Murphy T; Lu Y; Lalonde RG; Klein MB
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):463-9. PubMed ID: 17211282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada.
    Brunet L; Moodie EE; Cox J; Gill J; Cooper C; Walmsley S; Rachlis A; Hull M; Klein MB;
    HIV Med; 2016 Jan; 17(1):36-45. PubMed ID: 26140381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.
    Lin ZH; Xin YN; Dong QJ; Wang Q; Jiang XJ; Zhan SH; Sun Y; Xuan SY
    Hepatology; 2011 Mar; 53(3):726-36. PubMed ID: 21319189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
    Shaheen AA; Myers RP
    HIV Clin Trials; 2008; 9(1):43-51. PubMed ID: 18215981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond the Syndemic of Opioid Use Disorders and HIV: The Impact of Opioids on Viral Reservoirs.
    Trunfio M; Chaillon A; Beliakova-Bethell N; Deiss R; Letendre SL; Riggs PK; Higgins N; Gianella S
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632053
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.